Clinical Trials Logo

Myocardial Ischemia clinical trials

View clinical trials related to Myocardial Ischemia.

Filter by:

NCT ID: NCT00730132 Completed - Clinical trials for Hypercholesterolemia

Observational Study of Approaches to Lipid-Lowering Therapy in Russian Patients With Coronary Heart Disease <<Treat to Goal>> (Study P05464)

Start date: January 2008
Phase:
Study type: Observational

This study is being performed to evaluate what variants of lipid-lowering therapy are used in Russian clinical practice in coronary heart disease (CHD) patients with hypercholesterolemia in whom the initial statin therapy did not achieve low density lipoprotein-cholesterol (LDL-C) goals. Additionally, the efficacy and safety of all variants of modified lipid-lowering therapy are to be evaluated.

NCT ID: NCT00729040 Completed - Obesity Clinical Trials

Enhancing Adherence by Building Online Communities

Start date: January 2008
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine whether online peer support will increase adherence to an internet-based pedometer walking program.

NCT ID: NCT00728299 Completed - Clinical trials for Coronary Artery Disease

The Effects of Consumption of Pomegranate Juice on Carotid Intima-Media Thickness

Start date: September 2003
Phase: N/A
Study type: Interventional

Increases in carotid artery intima-media thickness (IMT) are correlated with increased risk of stroke and myocardial infarction. The purpose of this study is to assess if pomegranate juice will retard the carotid (IMT) progression rate in men and women who have one or more existing cardiovascular risk factors (current cigarette smoking, hypertension, low HDL-cholesterol, and/or high LDL-cholesterol) upon entrance into the study.

NCT ID: NCT00728156 Completed - Clinical trials for Coronary Artery Disease

Platelet-dependent Thrombosis: a Placebo-controlled Trial of Antiplatelet Therapy (Clopidogrel)

Start date: August 2009
Phase: Phase 4
Study type: Interventional

Patients with diabetes are more likely to develop furring of their coronary arteries and present with angina and heart attacks. Furthermore, after such an event, they have poorer outcomes (higher rates of death) and survivors are more likely to have recurring symptoms. Using a novel "clotting chamber" the investigators have shown that patients with diabetes are more likely to develop blood clots. This study will look at the role of different blood thinning medications in patients with diabetes. If successful, the investigators will provide evidence to conduct large clinical studies to look at the role of additional blood thinning medication in reducing heart attacks and strokes in patients with diabetes.

NCT ID: NCT00727051 Withdrawn - Clinical trials for Coronary Artery Disease

Comparison of Coronary CT Angiography With Conventional Coronary Angiography in Liver and Lung Transplant Candidates

Start date: June 2007
Phase:
Study type: Observational

The overall goal of this study is to determine if non-invasive imaging with state of the art CT coronary angiography can be used to screen for coronary artery disease in high risk patients prior to liver and lung transplantation. The current protocol for coronary artery disease assessment at UCSF before liver and lung transplantation involves screening with stress tests and/or coronary angiograms in patients with increased risk of coronary artery disease. Coronary angiogram will be used as gold standard for assessment of coronary CTA accuracy.

NCT ID: NCT00726921 Completed - Stroke Clinical Trials

Imaging Modalities in Detection of Coronary Artery Disease in End-stage Renal Disease Patients

Start date: August 25, 2008
Phase:
Study type: Observational

This study investigates hypothesizes that the combination of dobutamine stress echocardiography with dobutamine stress echocardiography with real time perfusion myocardial contrast echocardiography and coronary computed tomography is a better modality for detecting coronary artery disease in end-stage renal disease patients than coronary angiography, and in predicting patient outcomes. Demonstrating this would lead to increased use of DSE with RTCE and coronary CT at kidney transplant centers throughout the nation, leading to improved anatomical and functional detection of CAD without the need for further invasive procedures.

NCT ID: NCT00726453 Active, not recruiting - Clinical trials for Coronary Artery Disease

The Medtronic RESOLUTE US Clinical Trial

R-US
Start date: July 2008
Phase: N/A
Study type: Interventional

The objective of the study is to assess the safety and effectiveness of the Resolute Zotarolimus-Eluting Coronary Stent System for the treatment of de novo lesions in native coronary arteries with a reference vessel diameter (RVD) of 2.25 mm to 4.2 mm.

NCT ID: NCT00724880 Completed - Clinical trials for Coronary Artery Disease

Effect of Clopidogrel (Plavix) on Postoperative Bleeding in Patients Undergoing Coronary Artery Bypass Surgery.

Start date: June 2006
Phase: Phase 4
Study type: Interventional

- Running title: Effect of Clopidogrel on Postoperative Bleeding in Patients undergoing Coronary Artery Bypass Surgery - Title: Clopidogrel and bleeding in patients undergoing coronary artery bypass grafting. Is surgical delay necessary in patients using clopidogrel? And if so, which is the safety time interval when clopidogrel should be stopped before surgery in order to avoid bleeding and other related complications. - Background: By blockade of the platelet ADP receptor, clopidogrel inhibits the binding of fibrinogen to the platelet GPIIb/IIIa receptor complex, thereby preventing platelet aggregation from ADP stimulation. Some authors suggest that the platelet function is completely recovered in 7 days after stopping clopidogrel in healthy subjects. Other researches suggest full recovery of platelet function in 3 to 5 days. - Study objectives: To investigate if the interruption of the clopidogrel is necessary before CABG in order to prevent bleeding and other complications. To trace the increased risk patients for postoperative bleeding and to individualize the therapy according to TEG measurements. - Design: A prospective, randomized mono- center study - Patients: Patients who are receiving elective or urgent CABG surgery and are pre-treated at least 5 days before surgery with clopidogrel - Primary endpoint: To determine if there are significant differences in blood loss, transfusions and rethoracotomies in the three selected groups of patients treated with clopidogrel To asses the predictive value of the TEG clot strength in postoperative bleeding in patients using Clopidogrel. - Secondary endpoints: Death, myocardial infarction, stroke, respiratory failure, renal failure requiring dialysis, mediastinitis,readmission rates within 30 days from discharge, and ICU and hospital lengths of stay - Risks: Using standard dose of aprotinin, we consider no increased risk in blood loss and other related complications for this three groups of patients. - Possible benefits: Reduction of time delay in operating patients under treatment with clopidogrel. A more accurate time interval when clopidogrel should be stopped before surgery in order to eliminate the risk of bleeding and associated complications.

NCT ID: NCT00724542 Recruiting - Clinical trials for Coronary Heart Disease

Evaluation of Intervention on Impaired Glucose Tolerance(IGT) in Patients With Coronary Heart Disease.

EIIGETPCHD
Start date: July 2008
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether therapeutic intervention on impaired glucose tolerance in patients with coronary heart disease can decrease the incidence of new onset DM.

NCT ID: NCT00723723 Completed - Clinical trials for Hypercholesterolemia

Compliance With LDL-Lowering Therapy (Study P05467)(COMPLETED)

Start date: January 2008
Phase:
Study type: Observational

This observational study is being conducted in patients receiving statin treatment as secondary prevention of coronary heart disease under the current standard of care in compliance with European guidelines. The purpose of the study is to evaluate the percentage of these patients that reach target LDL levels. Additionally this study will measure the patient's compliance to treatment as assessed by counting the returned tablets. Both assessments will be made at visits conducted 6-8 weeks after the first visit and 28-32 weeks after the first visit.